Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1)

cic.isFulltext true es
cic.isPeerReviewed true es
cic.lugarDesarrollo Universidad Nacional de La Plata es
cic.version info:eu-repo/semantics/submittedVersion es 2016-08-17T14:29:57Z 2016-08-17T14:29:57Z
dc.title Breast cancer humoral immune response: involvement of Lewis y through the detection of circulating immune complexes and association with Mucin 1 (MUC1) en
dc.type Artículo es
dcterms.abstract In cancer patients, MUC1 glycoprotein may carry Lewis y which could be involved in immune response. Purposes: 1- to evaluate the presence of Lewis y and MUC1 in circulating immune complexes (Lewis y/CIC and MUC1/CIC, respectively) and their correlation; 2- to analyze the possible presence of Lewis y in carbohydrate chains of tumoral MUC1 glycoprotein and 3- to correlate serum and tissue parameters considered. Pretreatment serum and tissue breast samples from 76 adenocarcinoma, 34 benign and 36 normal specimens were analyzed. Anti-MUC1 and anti-Lewis y MAbs were employed. To detect Lewis y/CIC and MUC1/CIC, ELISA tests were developed; serum samples containing MUC1 were previously selected by Cancer Associated Serum Antigen (CASA). Immunoprecipitation (IP) was performed in 9 malignant, benign and normal samples and analyzed by SDS-PAGE and Western blot. Lewis y and MUC1 expression was studied by immunohistochemistry (IHC). Statistical analysis was performed employing principal component analysis (PCA), ANOVA, Tukey HSD, Chi square test and classical correlation (p < 0.05). By ELISA, Lewis y/IgM/CIC levels showed statistically significant differences between breast cancer versus benign and normal samples; mean +/- SD values expressed in OD units were: 0.525 +/- 0.304; 0.968 +/- 0.482 and 0.928 +/- 0.447, for breast cancer, benign disease and normal samples, respectively, p < 0.05. Lewis y/IgG/CIC did not show any statistically significant difference. MUC1/IgM/CIC correlated with Lewis y/IgM/CIC. By CASA, 9 samples with MUC1 values above the cut off were selected and IP was performed, followed by SDS-PAGE and Western blot; bands at 200 kDa were obtained with each MAb in all the samples. By IHC, with C14 MAb, 47.5%, 31% and 35% of malignant, benign and normal samples, respectively, showed positive reaction while all the samples were positive with anti-MUC1 MAb; in both cases, with a different pattern of expression between malignant and non malignant samples. Our findings support that in breast cancer there was a limited humoral immune response through Lewis y/IgM/CIC levels detection which correlated with MUC1/IgM/CIC. We also found that Lewis y might be part of circulating MUC1 glycoform structure and also that Lewis y/CIC did not correlate with Lewis y expression. en Isla Larrain, Marina Teresita es Demichelis, Sandra O. es Crespo, Marina es Lacunza, Ezequiel es Barbera, Alberto es Creton, Aldo es Terrier, Francisco es Segal-Eiras, Amada es Croce, María Virginia es
dcterms.extent 11 p. es
dcterms.identifier.other 1756-9966 es
dcterms.identifier.url Registro completo es
dcterms.isPartOf.issue vol. 28 es
dcterms.isPartOf.series Journal of Experimental & Clinical Cancer Research es
dcterms.issued 2009-01-01
dcterms.language Inglés es
dcterms.license Attribution 4.0 International (BY 4.0) es
dcterms.subject antigen antibody complex en
dcterms.subject breast tumor en
dcterms.subject cancer staging en
dcterms.subject immunology en
dcterms.subject pathology en
dcterms.subject.materia Ciencias Médicas y de la Salud es
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
croce - breast cancer.pdf-PDFA.pdf
2.33 MB
Adobe Portable Document Format
Documento completo